Financial Data and Key Metrics Changes - For Q4 2025, adjusted operating income was $586 million, bringing full-year adjusted operating income to $2.094 billion. Adjusted earnings per share (EPS) for Q4 was $3.40, with full-year adjusted EPS of $10.78. Free cash flow for Q4 was $309 million, totaling just over $1 billion for the full year [16][15][17] - Revenue per treatment (RPT) increased approximately $12 sequentially in Q4, with full-year RPT at approximately $410, reflecting a 4.7% increase year-over-year [17][18] - Patient care costs per treatment (PCCs) finished the year 5.9% higher than 2024, near the top end of revised expectations [18] Business Line Data and Key Metrics Changes - U.S. dialysis treatments declined by 1.1% for the full year 2025 compared to 2024, with a slight decline of about 20 basis points in Q4 [16][17] - International adjusted operating income was $21 million for Q4, totaling $114 million for the full year, reflecting strong performance and positive organic growth [18] - Integrated Kidney Care (IKC) achieved its first profitable year in 2025, with Q4 adjusted operating income of $46 million and full-year adjusted operating income of $22 million [18][19] Market Data and Key Metrics Changes - The company anticipates treatment volume for U.S. dialysis to be approximately flat in 2026, with expectations for RPT growth of 1%-2% [20][22] - The expiration of enhanced premium tax credits is expected to create a $40 million headwind in 2026, offset by the elimination of a $45 million headwind from a cyber incident in 2025 [22] Company Strategy and Development Direction - The company is focused on enhancing patient care through clinical initiatives, including vaccination programs and the adoption of GLP-1 medications, which are expected to improve patient outcomes and reduce mortality [11][12] - A strategic partnership with Elara Caring aims to establish an ESKD-focused offering to lower hospitalizations and improve patient experiences [12][24] - The company expects to deliver adjusted operating income growth of approximately 3.2% in 2026, with a focus on maintaining sustainable U.S. dialysis margins and delivering durable financial performance [15][22] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in sustaining profit growth despite near-term financial headwinds, emphasizing a focus on clinical excellence and targeted initiatives to enhance patient care [11][10] - The company anticipates that improvements in clinical outcomes will take time to materialize, with expectations for benefits to become evident in approximately two years [28][29] Other Important Information - The company repurchased nearly 13 million shares for approximately $1.8 billion in 2025, with a leverage ratio of 3.26 times consolidated EBITDA at year-end [19][24] - Free cash flow guidance for 2026 is set between $1 billion and $1.25 billion, reflecting a resilient business model [15][25] Q&A Session Summary Question: Confidence in returning to 2%+ volume growth - Management indicated that achieving 2% growth is tied to clinical improvements and expects to see benefits from initiatives in about two years [27][28] Question: Trends in mistreatments and mortality - Management noted that mistreatments were up in Q4 but did not see significant changes in mortality rates, emphasizing a correlation between mistreatment and mortality with some lag [35][36] Question: ACA headwind expectations - Management provided estimates for ACA headwinds, indicating better-than-expected performance during open enrollment but noted the need to monitor payment behaviors [39][40] Question: Impact of cyber incident on financials - Management clarified that the cyber incident created a $70 million headwind, with expectations for RPT headwinds to be offset by the expiration of enhanced premium tax credits [48] Question: Performance of IKC and future growth - Management highlighted that shared savings in IKC outperformed expectations due to improved care management and interventions, projecting continued growth [50][51] Question: International business growth and margins - Management expects international growth to be driven by both M&A and organic growth, with margins improving as fixed overhead is leveraged [61]

Core Viewpoint - DaVita projected annual profit above estimates following better-than-expected fourth-quarter results driven by steady demand for kidney dialysis services, resulting in a 13% increase in shares [1] Group 1: Financial Performance - DaVita reported fourth-quarter results that exceeded expectations, indicating strong operational performance [1] - The company’s projected annual profit is now above market estimates, reflecting confidence in future earnings [1] Group 2: Market Reaction - Following the announcement of the positive quarterly results and profit projections, DaVita's shares experienced a significant increase of 13% in after-hours trading [1]

Financial and operating highlights for the quarter and year ended December 31, 2025: | Three months ended | Year ended December 31, | | | | | --- | --- | --- | --- | --- | | December 31, 2025 | September 30, 2025 | 2025 | 2024 | | | Net income attributable to DaVita | (dollars in millions, except per | | | | | Inc.: | share data) | | | | | Net income from continuing | $ 209 | $ | $ | $ | | operations | | 150 | 722 | 936 | | Diluted per share from continuing | $ 2.94 | $ | $ | $ | | operations | | 2.04 | 9.5 ...

Industry Overview - Healthcare provider stocks are experiencing a decline due to higher operating expenses and ongoing debates over patient subsidies, which are pressuring earnings across the sector [1] - Hedge funds have become aggressive sellers, particularly in U.S. healthcare providers, with short positions in dialysis and hospital operators outnumbering long positions by approximately eight to one [1] Company Focus: DaVita (DVA) - DaVita, a leading kidney care services provider, has seen its short interest rise to about 11.6% of its float by year-end, marking a 12% increase in just one month, making it one of the most shorted stocks in the S&P 500 [2] - The stock has shifted from being a favorite of Warren Buffett, with Berkshire Hathaway reducing its stake, and DaVita shares are now trading near one-year lows [3] - Despite recent innovations and leadership changes aimed at driving growth, DaVita's shares have not gained traction and have fallen sharply, down about 36% over the past 52 weeks from a record high of nearly $177 to around $105 [5][6] Valuation Metrics - DaVita's current price-to-sales (P/S) ratio of 0.69 is significantly lower than the sector median of 4.01, indicating that the stock is undervalued relative to its peers [7] - The company's price-to-earnings (P/E) ratio of 12 represents a 54% discount compared to the sector median of 26, further suggesting attractive valuations [7]

Company Overview - DaVita Inc. (DVA) has a market cap of $7.3 billion and is a leading provider of kidney dialysis services in the U.S., operating outpatient dialysis centers and clinical laboratories for chronic kidney failure patients [1] - The company also offers hospital-based and home dialysis, integrated care programs, physician services, and comprehensive kidney care solutions [1] Financial Performance - Analysts expect DaVita to report an adjusted EPS of $3.24 for fiscal Q4 2025, a 44.6% increase from $2.24 in the same quarter last year [2] - For fiscal 2025, adjusted EPS is projected to be $10.70, up 10.5% from $9.68 in fiscal 2024, with further growth expected to $12.89 in fiscal 2026, representing a 20.5% year-over-year increase [3] Stock Performance - DaVita's shares have decreased by 36.1% over the past 52 weeks, underperforming the S&P 500 Index's 17% rise and the State Street Health Care Select Sector SPDR ETF's 11.3% gain during the same period [4] - Following the Q3 2025 results announcement, DaVita's shares fell by 6.2% due to an adjusted EPS of $2.51, which was below analyst estimates [5] Cost and Operational Challenges - The decline in Q3 2025 performance was attributed to higher patient care costs, which rose nearly 6% year-over-year to $271.23 per treatment, increased general and administrative expenses of $322 million, and lower dialysis volumes [5] - An April ransomware attack also impacted investor sentiment, costing the company $11.7 million and disrupting operations [6] Analyst Sentiment - The consensus view among analysts on DVA stock is cautious, with a "Hold" rating overall; among eight analysts, one recommends "Strong Buy," six suggest "Hold," and one indicates "Moderate Sell" [6] - The average analyst price target for DaVita is $141, indicating a potential upside of 34.8% from current levels [6]

Company Overview - Davita (DVA) is a leading provider of dialysis services and is the 16th-largest holding of Berkshire Hathaway (BRK.B) [1] - The stock has reached its 23rd new 52-week low at $104.24, reflecting a 37% decline over the past year [1] Berkshire Hathaway's Investment - Berkshire first acquired 2.68 million shares of Davita in Q4 2011, peaking at 38.57 million shares by the end of Q4 2014 [2] - As of the latest sale on October 27, 2025, Berkshire sold 401,514 shares at an average price of $135.36, reducing its holdings to 31.76 million shares, which is 1.1% of its $315 billion equity portfolio [2] - Despite the sales, Berkshire still owns 45.0% of Davita [2] Financial Performance - Over the 14 years of ownership, Davita's revenue has grown by 98%, from $6.73 billion in 2011 to $13.32 billion for the 12 months ending September 30, 2025, representing a 5.0% compound annual growth rate (CAGR) [6] - EBITDA has increased by 86% during the same period, with a 4.5% CAGR [6] Stock Price Volatility - Davita's stock has experienced significant volatility, with a price of around $85 in June 2015, dropping to half that by May 2019, then nearly tripling over the next two years before losing almost half of those gains in the following 18 months [5]

Core Insights - DaVita Inc. (DVA) is experiencing growth due to its business model, with optimism stemming from a solid third-quarter 2025 performance and international expansion, although concerns about reliance on commercial payers remain [1][7] Company Overview - DaVita has a market capitalization of $8.33 billion and projects a 12.6% growth over the next five years, maintaining strong performance [2] - The company has surpassed earnings estimates in three of the last four quarters, with an average surprise of 0.3% [2] Business Model - DaVita's patient-centric model integrates a comprehensive kidney care platform, enhancing patient choice and care coordination, particularly through value-based arrangements [3] - The company operates dialysis centers via joint ventures, typically holding controlling stakes, which support home dialysis options for eligible patients [4] International Expansion - DaVita is expanding its presence in international markets, particularly in Brazil, China, Colombia, Germany, India, Malaysia, Netherlands, Poland, Portugal, and Saudi Arabia through strategic alliances and acquisitions [5][8] - As of September 30, 2025, DaVita provided dialysis services to approximately 293,200 patients across 3,247 outpatient centers, with 585 centers located outside the U.S. [9] Financial Performance - DaVita reported mixed results for Q3 2025, with positive trends in revenue and treatment volume, but a year-over-year decline in net income [10][11] - The Zacks Consensus Estimate for Q4 2025 revenues is $3.53 billion, reflecting a 6.9% increase year-over-year, while earnings are expected to decline by 49.11% [14] Challenges - The company faces challenges due to its dependence on commercial payers, with a significant portion of revenues coming from commercially insured patients, which is under pressure [12] - Rising unemployment may lead to a shift from commercial plans to government coverage, potentially compressing margins and affecting profitability [13]

Company Overview - DaVita Inc. (DVA) has a market capitalization of $8.6 billion and is a leading provider of kidney dialysis services in the United States, operating a nationwide network of outpatient dialysis centers [1] - The company offers a range of services including outpatient, inpatient, and home-based hemodialysis, as well as related laboratory testing for patients with end-stage renal disease (ESRD) [1][2] Financial Performance - DVA shares have decreased 32.4% from their 52-week high of $179.60 and have dropped 8.9% over the past three months, underperforming the Dow Jones Industrials Average, which rose by 5.7% in the same period [3] - Year-to-date, DVA stock has dipped 18.9%, while the Dow Jones has gained 13.9% [4] - Over the past 52 weeks, DVA shares have declined 21.2%, compared to a 10.4% return for the Dow Jones [4] - Following the Q3 2025 results released on October 29, DVA shares tumbled 6.2%, reporting an adjusted EPS of $2.51, which was below analyst estimates [5] - The decline in earnings was attributed to higher patient care costs, which rose nearly 6% year-over-year to $271.23 per treatment, increased general and administrative expenses of $322 million, and lower dialysis volumes [5] Operational Challenges - Investor sentiment has been negatively impacted by an April ransomware attack that cost the company $11.7 million and disrupted operations [6] - DVA has underperformed compared to its rival HCA Healthcare, Inc. (HCA), which has seen its stock climb 60.4% year-to-date and 53.4% over the past year [6] Analyst Sentiment - Analysts are cautious about DVA's prospects, with a consensus rating of "Hold" among the eight analysts covering the stock [7] - The mean price target for DVA is $143, indicating a potential premium of 17.8% to current levels [7]

Q3 2025 Performance Highlights - Strong organic revenue growth of 9.7% was supported by all three operating segments[9, 27, 31] - Accelerated operating income growth of 28% at constant currency led to a step-change in margin expansion to 11.7%[9, 29, 31] - FME25+ savings of EUR 47 million continued momentum[9] - The company repurchased 3.6 million shares, representing 1.2% of share capital, for EUR 151 million[9, 56] Segment Performance - Care Delivery: Revenue increased by 3.6% at constant currency, with U S organic growth of 5.8% driven by favorable rate/mix effects[36, 39] Operating income increased by 14.4% at constant currency[37] - Value-Based Care: Revenue increased by 42.1% at constant currency, driven by a significantly higher number of member months[41, 42] - Care Enablement: Revenue increased by 4.6% at constant currency[47] Operating income increased by 38.1% at constant currency, with margin expansion to 7.6%[49] Financial Position - Total net debt and lease liabilities decreased to EUR 9,218 million compared to EUR 9,831 million in Q3 2024, a decrease of 6%[52] - Net leverage ratio improved to 2.6x, compared to 2.9x at FY 2024 and 3.41x in Q3 2024[54] - Operating cash flow was EUR 742 million, a decrease of 25% compared to EUR 985 million in the prior year, which was inflated by around EUR 400 million following the cyber incident at Change Healthcare[52, 55] Outlook - The company confirmed its FY 2025 outlook, expecting revenue to grow positively to a low-single digit percent and operating income to grow in the high-teens to high-twenties percent, both on a constant currency basis and excluding special items[58, 59] The implied Group operating income margin is expected to be around 11% to 12%[59]

Core Viewpoint - Fresenius Medical Care reported a third-quarter operating income that exceeded analysts' expectations, indicating that the company's cost-cutting measures are starting to yield positive results [1] Financial Performance - The operating income for the third quarter surpassed analysts' forecasts, suggesting effective management of operational costs [1] Cost-Cutting Measures - The positive financial results are attributed to the implementation of cost-cutting strategies, which are beginning to show their impact on the company's profitability [1]